hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported 13 hours ago - Updated 13 hours ago - 1 reports

New Cell Proliferation Findings from Novartis Institutes for Biomedical Research Described (Pim2 is required for maintaining multiple myeloma cell...

New Cell Proliferation Findings from Novartis Institutes for Biomedical Research Described (Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation)By a News Reporter-Staff News Editor at Health & Medicine ... [Published 4 Traders - 13 hours ago]
First reported Oct 19 2014 - Updated Oct 19 2014 - 1 reports

ASH elects four executive committee members

ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD , will serve a 1-year term as vice president, followed by successive terms as president-elect and president. Anderson is director of the ... [Published Orthopedics Today - Oct 19 2014]
First reported Oct 15 2014 - Updated Oct 16 2014 - 1 reports

CARs Motor Through Leukemia, Part 2: 'Landscape Changing'

For the second time this week, clinical details of the remarkable responses in acute lymphoblastic leukemia (ALL) seen with chimeric antigen receptor (CAR)-modified T-cells have been published."This whole field has just exploded. It probably represents ... [Published American Journal of Public Health - Oct 15 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

NOL3 is a predictor of patient outcome

Dana-Farber Cancer Institute, Inc. (Ann Arbor, MI)Family ID:Appl. No.:January 11, 2010The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer ... [Published PharmCast - Oct 10 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

BIOTEST : Patent Issued for Immunoconjugates Targeting Syndecan-1 Expressing Cells and Use

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Alexandria, Virginia , NewsRx journalists report that a patent by the inventor Goldmakher, Viktor S. ( Newton, MA ), filed on April 16, 2007 , was published online on September ... [Published 4 Traders - Oct 04 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma [Hematologic Malignancy]

AbstractPurpose We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuselarge B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients ... [Published Journal of Clinical Oncology - Sep 30 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Anchors Away

October 2014 , Volume 29 , Issue 10 , pp 1414-1418Date:20 May 2014Rent the article at a discountRent now* Final gross prices may vary according to local VAT.Get AccessThis is an excerpt from the contentIn this series, a clinician extemporaneously discusses ... [Published Springer Link Journal - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide [Hematologic Malignancy]

PurposeArsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). QT interval prolongation is common with ATO and can pose a barrier to effective administration. The objective of this study was to characterize ... [Published Journal of Clinical Oncology - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial [Hematologic Malignancy]

PurposeThe introduction of all- trans -retinoic acid (ATRA) has significantly improved outcomes for acute promyelocytic leukemia (APL), although a subset of patients still suffer relapse. The purpose of this study was to evaluate the role of maintenance ... [Published Journal of Clinical Oncology - Sep 23 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Updated Summary: ACR Appropriateness Criteria® rib fractures. [American College of Radiology]

ACR Appropriateness Criteria®Clinical Condition : Rib FractureVariant 1 : Adult. Suspected rib fractures from minor blunt trauma (injury confined to ribs).Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" fie ... [Published National Guideline Clearinghouse - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced...

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced Hematologic MalignanciesBy a News Reporter-Staff News Editor at Clinical Trials Week Boston Strategics Corporation ... [Published Pharmacy Choice - Sep 15 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ... [Published Marketwire - Breaking News Releases - Jun 12 2014]

Quotes

According to the news editors, the research concluded: "These findings support Pim2 as a promising therapeutic target for MM and define a novel Pim2-TSC2-mTOR-C1 pathway that drives MM proliferation."
..."You force it into reacting to the cancer by introducing the CAR into the patient's own T-cells," he said. "You engineer the patient's own immune system into recognizing and destroying the cancer, but this revving up of the immune system also has side effects.... These bombs are smart, but they are not that smart" he said. They destroy cancer cells, but they also destroy normal cells that are very similar
"The cytotoxicity of the effector molecule, in its native form, on cells targeted by said targeting antibody may be higher or about the same as the cytotoxicity of the immunoconjugate on said targeted cells. The effector molecule may have, in its native form, a potency of about 10.sup.-14-10.sup.-7, preferably a potency of about 10.sup.-13-10.sup.-7M, of about 10.sup.-12-10.sup.-7M, of about 10.sup.-12-10.sup.-8M, most preferably of about 10.sup.-11-10.sup.-8 M, which includes any narrower potency ranges encompassed by the ranges specified above, such as, but not limited to, a potency of about 10.sup.-11-10.sup.-10 M The effector molecule may be a maytansinoid, in particular DM1, DM3 or DM4, a CC1065 analogue, a calicheamicin or a taxane. In certain embodiments, the effector molecule may have a molecular weight of less than 5 kDa, in particular less than 2 kDa, more in particular less than 1 kDa and in between about 600 and about 800 Da."

More Content

All (13) | News (12) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New Cell Proliferation Findings from Novartis I... [Published 4 Traders - 13 hours ago]
ASH elects four executive committee members [Published Orthopedics Today - Oct 19 2014]
CARs Motor Through Leukemia, Part 2: 'Landscape... [Published American Journal of Public Health - Oct 15 2014]
NOL3 is a predictor of patient outcome [Published PharmCast - Oct 10 2014]
BIOTEST : Patent Issued for Immunoconjugates Ta... [Published 4 Traders - Oct 04 2014]
Utility of Routine Post-Therapy Surveillance Im... [Published Journal of Clinical Oncology - Sep 30 2014]
Anchors Away [Published Springer Link Journal - Sep 26 2014]
Prevalence, Management, and Clinical Consequenc... [Published Journal of Clinical Oncology - Sep 23 2014]
Tamibarotene As Maintenance Therapy for Acute P... [Published Journal of Clinical Oncology - Sep 23 2014]
Updated Summary: ACR Appropriateness Criteria® ... [Published National Guideline Clearinghouse - Sep 15 2014]
Boston Strategics Corporation Initiates a Phase... [Published Pharmacy Choice - Sep 15 2014]
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.